Table 4.
Association of the KIRs with Taiwanese AS susceptibility and clinical phenotypes.
| Characteristics | Killer Immunoglobulin-like Receptors (KIRs) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| *2DS1 | 2DS2 | 2DS3 | 2DS4 del | 2DS4 ful | 2DS5 | 3DS1 | 2DL2 | 2DL5 | |
| Disease | |||||||||
| AS | 218 (33.38%) | 160 (24.5%) | 134 (20.52%) | 353 (54.06%) | 507 (77.64%) | 143 (21.9%) | 225 (34.46%) | 176 (26.95%) | 256 (39.2%) |
| Normal | 352 (36.97%) | 219 (23%) | 202 (21.22%) | 466 (48.95%) | 743 (78.05%) | 235 (24.68%) | 361 (37.92%) | 231 (24.26%) | 441 (46.32%) |
| p-value | 0.1399 | 0.4876 | 0.7363 | 0.0444 | 0.8477 | 0.1965 | 0.1569 | 0.2242 | 0.0047 |
| p-value (FDR) | 0.3363 | 0.626914286 | 0.8283375 | 0.1998 | 0.8477 | 0.3363 | 0.3363 | 0.3363 | 0.0423 |
| OR (95% CI) | 0.85 (0.69–1.05) | 1.09 (0.86–1.37) | 0.96 (0.75–1.23) | 1.23 (1.01–1.5) | 0.98 (0.77–1.24) | 0.86 (0.68–1.08) | 0.86 (0.7–1.06) | 1.15 (0.92–1.45) | 0.75 (0.61–0.91) |
| Sex | |||||||||
| Male | 379 (34.36%) | 261 (23.66%) | 226 (20.49%) | 569 (51.59%) | 855 (77.52%) | 255 (23.12%) | 401 (36.36%) | 277 (25.11%) | 480 (43.52%) |
| Female | 191 (38.05%) | 118 (23.51%) | 110 (21.91%) | 250 (49.8%) | 395 (78.69%) | 123 (24.5%) | 185 (36.85%) | 130 (25.9%) | 217 (43.23%) |
| p-value | 0.1526 | 0.9454 | 0.5161 | 0.5070 | 0.6008 | 0.5449 | 0.8477 | 0.7372 | 0.9133 |
| p-value Characteristic | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 | 0.9454 |
| OR (95% CI) | 0.85 (0.68–1.06) | 1.01 (0.79–1.29) | 0.92 (0.71–1.19) | 1.07 (0.87–1.33) | 0.93 (0.72–1.21) | 0.93 (0.72–1.19) | 0.98 (0.79–1.22) | 0.96 (0.75–1.22) | 1.01 (0.82–1.25) |
| Syndesmophyte | |||||||||
| Positive | 101 (32.79%) | 68 (22.08%) | 56 (18.18%) | 160 (51.95%) | 234 (75.97%) | 69 (22.4%) | 106 (34.42%) | 74 (24.03%) | 116 (37.66%) |
| Negative | 117 (33.91%) | 92 (26.67%) | 78 (22.61%) | 193 (55.94%) | 273 (79.13%) | 74 (21.45%) | 119 (34.49%) | 102 (29.57%) | 140 (40.58%) |
| p-value | 0.7619 | 0.1740 | 0.1627 | 0.3067 | 0.3334 | 0.7686 | 0.9835 | 0.1118 | 0.4465 |
| p-value (FDR) | 0.864675 | 0.522 | 0.522 | 0.60012 | 0.60012 | 0.864675 | 0.9835 | 0.522 | 0.66975 |
| OR (95% CI) | 0.95 (0.69–1.32) | 0.78 (0.54–1.12) | 0.76 (0.52–1.12) | 0.85 (0.63–1.16) | 0.83 (0.58–1.21) | 1.06 (0.73–1.53) | 1 (0.72–1.38) | 0.75 (0.53–1.07) | 0.88 (0.65–1.21) |
| B27 | |||||||||
| Positive | 196 (32.61%) | 144 (23.96%) | 118 (19.63%) | 326 (54.24%) | 468 (77.87%) | 132 (21.96%) | 202 (33.61%) | 158 (26.29%) | 231 (38.44%) |
| Negative | 22 (42.31%) | 16 (30.77%) | 16 (30.77%) | 27 (51.92%) | 39 (75%) | 11 (21.15%) | 23 (44.23%) | 18 (34.62%) | 25 (48.08%) |
| p-value | 0.1573 | 0.2749 | 0.0595 | 0.7475 | 0.6339 | 0.8923 | 0.1246 | 0.1966 | 0.1739 |
| p-value (FDR) | 0.35388 | 0.41235 | 0.35388 | 0.8409375 | 0.815014286 | 0.8923 | 0.35388 | 0.35388 | 0.35388 |
| OR (95% CI) | 0.66 (0.37–1.17) | 0.71 (0.38–1.31) | 0.55 (0.3–1.02) | 1.1 (0.62–1.94) | 1.17 (0.61–2.26) | 1.05 (0.52–2.1) | 0.64 (0.36–1.13) | 0.67 (0.37–1.23) | 0.67 (0.38–1.19) |
| Age onset | |||||||||
| ≤16 | 27 (28.72%) | 28 (29.79%) | 21 (22.34%) | 51 (54.26%)) | 77 (81.91%) | 16 (17.02%) | 26 (27.66%) | 29 (30.85%) | 36 (38.3%)) |
| >16 | 191 (34.17%) | 132 (23.61%) | 113 (20.21%) | 302 (54.03%) | 430 (76.92%) | 127 (22.72%) | 199 (35.6%) | 147 (26.3%) | 220 (39.36%) |
| p-value | 0.1598 | 0.1344 | 0.6630 | 0.4633 | 0.3844 | 0.1514 | 0.0689 | 0.1244 | 0.3841 |
| p-value (FDR) | 0.28764 | 0.28764 | 0.663 | 0.5212125 | 0.494228571 | 0.28764 | 0.28764 | 0.28764 | 0.494228571 |
| OR (95% CI) | 1.38 (0.88–2.17) | 0.71 (0.45–1.11) | 0.9 (0.55–1.47) | 0.86 (0.57–1.29) | 0.79 (0.47–1.34) | 1.48 (0.87–2.53) | 1.53 (0.97–2.41) | 0.71 (0.45–1.1) | 1.21 (0.79–1.83) |
*2DS1: Two Ig Domains and Short cytoplasmic tail 1.